Stifel Nicolaus Forecasts Strong Price Appreciation for HLS Therapeutics (TSE:HLS) Stock

HLS Therapeutics (TSE:HLS) had its price objective upped by equities researchers at Stifel Nicolaus from C$3.50 to C$4.00 in a research report issued on Wednesday,BayStreet.CA reports. The firm currently has a “hold” rating on the stock. Stifel Nicolaus’ price target indicates a potential downside of 11.50% from the company’s previous close.

HLS Therapeutics Stock Performance

Shares of HLS opened at C$4.52 on Wednesday. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. HLS Therapeutics has a 52-week low of C$3.00 and a 52-week high of C$5.48. The stock has a 50 day moving average price of C$4.18 and a 200 day moving average price of C$3.80. The company has a market capitalization of C$100.56 million, a price-to-earnings ratio of -4.53 and a beta of 1.07.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.